Results 121 to 130 of about 61,637 (294)

Spina bifida as a multifactorial birth defect: Risk factors and genetic underpinnings

Pediatric Discovery, EarlyView.
Abstract Spina bifida is a birth defect resulting from abnormal embryonic development of the neural tube. Though spina bifida is divided into several subtypes, myelomeningocele—the most severe form of spina bifida often associated with a markedly diminished quality of life—accounts for a significant portion of cases.
Ethan S. Wong, Daniel A. Hu, Lily Zhang, Rachel Qi, Cindy Xu, Ou Mei, Guowei Shen, Wulin You, Changqi Luo, Tong‐Chuan He, Russell R. Reid, Lewis S. Shi, Michael J. Lee, Yi Zhu   +13 more
wiley   +1 more source

Polymer type effect on microparticle blend of ethyl cellulose, poly(lactic‐co‐glycolic acid) and poly(ε‐caprolactone) for controlled drug delivery with varying solubility

Polymer International, EarlyView.
Preparation, possible microparticles formed, morphology of microparticles and drug release profile from polymeric microparticles. Abstract The objective of this study was to investigate the impact of polymer type on polymeric microparticle blends designed for controlled drug delivery. Microparticle blends containing a single drug (propranolol HCl [Pro]
Muhaimin Muhaimin, Roland Bodmeier
wiley   +1 more source

Physiologically based pharmacokinetic modeling and simulation of topiramate in populations with renal and hepatic impairment and considerations for drug–drug interactions

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 510-522, March 2025.
Abstract Topiramate (TPM) is a broad‐spectrum antiepileptic drug (AED) commonly prescribed for approved and off‐label uses. Routine monitoring is suggested for clinical usage of TPM in special population due to its broad side effect profile. Therefore, it is crucial to further explore its pharmacokinetic characteristics.
Shuqing Chen, Chaozhuang Shen, Yuchen Tian, Yuhe Peng, Jing Hu, Haitang Xie, Ping Yin   +6 more
wiley   +1 more source

Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update

Clinical pharmacology and therapy, 2018
E. Phillips, C. Sukasem, Michelle Whirl‐Carrillo, D. Müller, H. M. Dunnenberger, W. Chantratita, B. Goldspiel, Yuan-Tsong Chen, B. Carleton, A. George, T. Mushiroda, T. Klein, Roseann S. Gammal, M. Pirmohamed   +13 more
semanticscholar   +1 more source

Autonomous Changes in Polymer Materials Driven by Chemical Fuels

ChemSystemsChem, EarlyView.
Inspired by out‐of‐equilibrium reaction networks in biochemical systems, chemical fuel reactions have been developed that impart time‐dependent properties to polymer materials. This review describes recent advances in the development of materials exhibiting transient changes in phase, mechanical properties, swelling, self‐healing, and self‐assembly ...
Chamoni W. H. Rajawasam, Dominik Konkolewicz, C. Scott Hartley   +2 more
wiley   +1 more source

Effect of zeolites on the reduction of the ecotoxicity of carbamazepine in the environment

Ecotoxicology and Environmental Safety
In this study, the impact of calcination of zeolites on the ecotoxicity of carbamazepine solutions in two matrices, water and synthetic sewage, was assessed.
Aleksandra Bogusz, Beata Tomczyk, Magdalena Trzcińska, Barbara Mirosław, Barbara Gworek   +4 more
doaj  

Treatment of Early‐Onset Specified and Unspecified Bipolar Disorders: A Systematic Review and Strategies for Identifying and Managing a Thermally Dysregulated Subtype in Children

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Introduction Bipolar disorder (BD), characterized by extreme mood shifts between mania and depression, can manifest in childhood, and pose treatment challenges. Treatment for full‐criteria BD I or II in children has been partially described in the literature, but major uncertainties exist regarding non‐classic presentations, which were ...
Demitri F. Papolos, Martin H. Teicher, Robert M. Post   +2 more
wiley   +1 more source

Opportunities and Challenges of Population Pharmacogenomics

Annals of Human Genetics, EarlyView.
ABSTRACT Pharmacological responses can vary significantly among patients from different ethnogeographic backgrounds. This variability can, at least in part, be attributed to population‐specific genetic patterns in genes involved in drug absorption, distribution, metabolism, and excretion, as well as in genes associated with drug‐induced toxicity ...
Yitian Zhou, Yoomi Park, Mahamadou D. Camara, Volker M. Lauschke   +3 more
wiley   +1 more source

Ocular Neuromyotonia—A Rare but Reversible Cause of Intermittent Diplopia

Movement Disorders Clinical Practice, EarlyView.
Parthvi Ravat, Paul Stockle, Mahadya Rahman, Pegah Ahmadiyan Ardestani, Andrew Lee   +4 more
wiley   +1 more source

Embedding Pharmacogenetics Into Clinical Practice to Improve Patient Outcomes

Annals of Human Genetics, EarlyView.
ABSTRACT Pharmacogenomics, the use of germline genomic data to guide prescription to improve effective and safer medication, holds promise as a clinical intervention. To date in most health systems, there has been limited uptake of pharmacogenomic testing confined to a few single drug–gene associations.
John Henry McDermott, Videha Sharma, Jessica Keen, William Gerard Newman   +3 more
wiley   +1 more source